Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
| MarketCap | 15.5B |
|---|---|
| PE Ratio | -59.5 |
| PEG Ratio | -5.3 |
| P/B | 11.4 |
| P/S (ttm) | 51.4 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 5% |
| Held by Institutions % | 80% |
| 1 Day Vol Adjusted Return | 0.5 |
| 1 Month Vol Adjusted Return | -0.2 |
| 3 Month Vol Adjusted Return | 10.4 |
| 6 Month Vol Adjusted Return | 20.8 |
| 20 Days SMA Price ZScore | -0.9 |
| 50 Days SMA Price ZScore | 0.2 |
| 12 -26 Days PPO | 0.2 |
| 1 Month Average Short Volume Ratio | 42.7 |
| 1 Day Volume Change ZScore | 0.1 |
| 1 Month Daily Vol | 3.2 |
Stock news
Guardant Health, Inc. (Nasdaq: GH) has CE-marked Guardant360® CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). The test is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib).
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Shares of Guardant Health (NASDAQ: GH) were sinking 7.2% as of 11:08 a.m. EST on Thursday. Guardant Health announced Q4 revenue of $78.3 million, up 25% year over year and higher than the average analyst estimate of $76.7 million. It's not unusual for growth stocks like Guardant Health to fall quite a bit after missing a quarterly earnings estimate.
The company beat revenue expectations, but its bottom-line performance and 2021 outlook weren't what investors hoped for.
Ladies and gentlemen, thank you for standing by, and welcome to the Guardant Health Q4 2020 Earnings Conference Call. Earlier today, Guardant Health released financial results for the quarter and full year ended December 31, 2020. Joining me today from Guardant Health is Helmy Eltoukhy, Chief Executive Officer; AmirAli Talasaz, President; and Mike Bell, Chief Financial Officer.
Shares of Guardant Health (NASDAQ:GH) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 248.15% over the past year to ($0.94), which missed the estimate of ($0.57). Revenue of $78,316,000 up by 24.51% year over year, which beat the estimate of $76,730,000. Looking Ahead Guardant Health hasn't issued any earnings guidance for the time being. The upcoming fiscal year's revenue expected to be between $360,000,000 and $370,000,000. Con...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2020.